168 related articles for article (PubMed ID: 34230441)
1. Immunotherapy in rare ovarian cancer.
Laga T; Vergote I; Van Nieuwenhuysen E
Curr Opin Oncol; 2021 Sep; 33(5):447-456. PubMed ID: 34230441
[TBL] [Abstract][Full Text] [Related]
2. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.
Groen RS; Gershenson DM; Fader AN
Gynecol Oncol; 2015 Feb; 136(2):373-83. PubMed ID: 25481800
[TBL] [Abstract][Full Text] [Related]
3. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
Hollis RL
Cancer Lett; 2023 Feb; 555():216057. PubMed ID: 36627048
[TBL] [Abstract][Full Text] [Related]
5. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
6. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
7. New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer-A Systematic Review.
Bachmann C
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001616
[TBL] [Abstract][Full Text] [Related]
8. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
[TBL] [Abstract][Full Text] [Related]
9. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
[TBL] [Abstract][Full Text] [Related]
11. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
12. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Maiorano BA; Lorusso D; Maiorano MFP; Ciardiello D; Parrella P; Petracca A; Cormio G; Maiello E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409229
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
McCluggage WG; Young RH
Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Rare Epithelial Ovarian Tumors.
Cobb LP; Gershenson DM
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1011-1024. PubMed ID: 30390757
[TBL] [Abstract][Full Text] [Related]
15. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
Semin Cancer Biol; 2022 Nov; 86(Pt 3):207-223. PubMed ID: 35395389
[TBL] [Abstract][Full Text] [Related]
16. Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation.
Taylor EC; Irshaid L; Mathur M
Radiographics; 2021; 41(1):289-315. PubMed ID: 33186060
[TBL] [Abstract][Full Text] [Related]
17. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression.
Federici MF; Kudryashov V; Saigo PE; Finstad CL; Lloyd KO
Int J Cancer; 1999 Apr; 81(2):193-8. PubMed ID: 10188718
[TBL] [Abstract][Full Text] [Related]
18. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
[TBL] [Abstract][Full Text] [Related]
20. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]